About The Author

Editorial & Columns

Valuation Premium: India-listed Subsidiaries of Pharma and Healthcare MNCs Outshine Parent firms

June 26, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

India and Group of Seven (G7): Connected through Pharmaceuticals

June 21, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Accessibility and Affordability of Biologics in Low-Middle Income Countries

June 12, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

ESG Frameworks and Pharmaceutical Industry in India

June 6, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Exchange Rate Fluctuations : Effects on Pharmaceutical Sector in SAARC Nations

May 29, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Inflation and Pharmaceutical Products: A Global Concern

May 22, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Skin in the Game: Promoter Holding in Indian Pharmaceutical Companies

May 15, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

India-Australia Economic Cooperation and Trade Agreement & Pharmaceutical Exports from India

May 9, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Pharma 2.0: Indian Pharmaceutical Companies strive to Create & Enhance Strength in Biopharmaceuticals

May 2, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Patent Expiry & Innovator Pharmaceutical Companies : Mechanisms applied to preserve market dominance

April 24, 2024 | Dr. Anil Kumar Angrish | No Comments |

More